LC350189 + naproxen

LC350189 + naproxen is a **combination drug consisting of LC350189 and naproxen**. LC350189 is an investigational drug; its precise class and mechanism of action are not stated in the provided references, but it is being evaluated for pharmacokinetic and pharmacodynamic interactions with naproxen[1][4]. Naproxen is a well-established nonsteroidal anti-inflammatory drug (NSAID) that acts primarily as a cyclo-oxygenase inhibitor, reducing the synthesis of prostaglandins involved in pain, inflammation, and fever. This combination is currently under clinical investigation for drug-drug interaction, safety, and tolerability profiles in healthy adults, not for a particular disease indication[1][4]. There is no indication that this combination is approved or marketed for any therapeutic use to date.